Vice President & CMO of Clinical and Molecular Pathology, PathGroup
Dr. Chandra is an experienced physician leader and molecular/genomic and clinical pathologist with board certifications in anatomic and clinical pathology, molecular genetic pathology, and hematopathology. His clinical genomics experience includes sign out various molecular and genomics assays including next generation sequencing, array comparative genomic hybridization, IHC, ISH, and PCR-based tests. In his current role, Dr. Chandra provides clinical and administrative leadership to Molecular Pathology and Genomic Medicine Operations at PathGroup. He also similarly oversees Operations in Clinical Pathology. Together, this testing represents 60% of PathGroup revenue.
Dr. Chandra is also an internal and external consultant to guide molecular test selection and development, adoption of molecular biomarker testing in community practice, algorithmic testing standardization, appropriate molecular test utilization, and corporate molecular business strategy. He is passionate about driving the adoption of value-based Personalized and Precision Oncology and is considered a thought-leader in this space. Dr. Chandra has worked with and guided many pharmaceutical organizations including Pfizer, Bristol-Myers Squibb, Astra Zeneca, and Roche.
During his 5+ year tenure at PathGroup, Dr. Chandra has led their divisions to national recognition. In 2015, PathGroup performed greater than 1 million genomic tests and close to 6 million clinical pathology tests, more than doubled net revenues, and achieved global reduction in operational testing cost.